AEON

AEON Biopharma Inc

0.2399

Oct 23 • 3:59 PM ET +0.0062 (2.65%)

0.2415

Aftermarket • 6:10 PM ET +0.0016 (0.67%)

Healthcare Biotechnology USA Nano AMEX

Peers: EOLS MANE TNXP VRCA AXSM CNXU ACRS ARQT SKYE XBIT

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	11.97M
Enterprise Value	11.31M
Income	-54.62M
Sales	0.00M
Book/sh	-0.58
Cash/sh	0.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Apr 12, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	3.49
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.54
Current Ratio	0.54
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-3.77
EPS next Y	-0.28
EPS next Q	-0.08
EPS this Y	89.32%
EPS next Y	33.06%
EPS next 5Y	67.95%
EPS past 3/5Y	47.46% -253.12%
Sales past 3/5Y	- -
EPS Y/Y TTM	35.03%
Sales Y/Y TTM	-
EPS Q/Q	96.18%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	91.11% -

Insider Own	52.32%
Insider Trans	4.61%
Inst Own	31.71%
Inst Trans	50.51%
ROA	-621.70%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.77%
SMA50	-6.68%
SMA200	-65.62%
Trades

Shs Outstand	26.31M
Shs Float	23.78M
Short Float	9.13%
Short Ratio	0.29
Short Interest	2.17M
52W High	1.45 -83.46%
52W Low	0.18 35.38%
Volatility	6.35% 13.06%
ATR (14)	0.03
RSI (14)	44.71
Beta	0.69
Rel Volume	0.03
Avg Volume	7.52M
Volume	199,470

Perf Week	3.41%
Perf Month	-7.80%
Perf Quarter	-7.73%
Perf Half Y	-77.15%
Perf YTD	-78.19%
Perf Year	-73.60%
Perf 3Y	-99.94%
Perf 5Y	-99.97%
Perf 10Y	-
Recom	1.00
Target Price	1.82
Prev Close	0.23
Price	0.24
Change %	2.65%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Initiated	Laidlaw	Buy	$1.80
Jul-30-26	Initiated	Lake Street	Buy	$1
Aug-18-23	Initiated	H.C. Wainwright	Buy	$18

Oct-09-26 04:15PM	AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) -10.97% -11.01%
Sep-30-26 08:00AM	AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 (GlobeNewswire) +15.83%
Sep-09-26 08:00AM	AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX (GlobeNewswire)
Aug-31-26 08:00AM	AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference (GlobeNewswire) -5.82%
Aug-24-26 08:00AM	AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer (GlobeNewswire)
08:00AM	Loading…
Aug-19-26 08:00AM	AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX (GlobeNewswire) -19.02%
Aug-12-26 04:15PM	AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-26 04:15PM	AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards (GlobeNewswire)
Jul-30-26 09:38AM	Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls (The Fly) +5.02%
Jul-14-26 08:00AM	AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding (GlobeNewswire) +10.84%
Jun-04-26 07:00AM	AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society (GlobeNewswire)
May-14-26 04:05PM	AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -9.91%
Apr-24-26 04:05PM	AEON Biopharma Sets Annual Shareholder Meeting (GlobeNewswire)
Apr-03-26 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards (GlobeNewswire)
04:05PM	Loading…
Mar-30-26 04:05PM	AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program (GlobeNewswire) -14.70%
Mar-25-26 08:00AM	AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program (GlobeNewswire)
Mar-09-26 04:05PM	AEON Biopharma Appoints John Bencich as Chief Financial Officer (GlobeNewswire) +7.48%
Mar-05-26 04:05PM	AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -5.50%
Jan-21-26 04:05PM	AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions (GlobeNewswire) +13.33% -13.97%
Dec-19-25 06:00PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +6.93%
Dec-15-25 04:05PM	AEON Biopharma Announces Execution of Exchange Agreement with Daewoong (GlobeNewswire) +5.10% +19.21%
Nov-20-25 08:30AM	AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling (GlobeNewswire) -12.79%
Nov-14-25 08:30AM	AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth (GlobeNewswire)
Aug-12-25 04:05PM	AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +16.08%
May-23-25 04:05PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +13.67%
May-19-25 04:05PM	AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 (GlobeNewswire)
May-14-25 04:05PM	AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-25 04:05PM	AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -6.43%
Apr-21-25 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	Loading…
04:05PM	AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer (GlobeNewswire)
Mar-27-25 04:05PM	AEON Biopharma Announces CEO Transition (GlobeNewswire) -8.56% -7.34%
Mar-24-25 04:05PM	AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +8.03% -7.28%
Mar-04-25 08:00AM	AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -21.31%
Feb-24-25 02:00PM	AEON Biopharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -43.89%
Feb-07-25 04:05PM	AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) -6.93%
Jan-07-25 09:37AM	AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering (GlobeNewswire) +5.24%
Jan-06-25 09:00AM	AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering (GlobeNewswire) -63.09%
Jan-03-25 08:02PM	AEON Biopharma, Inc. Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-13-24 04:05PM	AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.11% -11.35%
Sep-30-24 08:00AM	AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting (GlobeNewswire) +13.18%
Aug-21-24 09:55AM	AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-19-24 04:05PM	AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (GlobeNewswire)
Aug-12-24 04:05PM	AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-24 08:00AM	AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450 (GlobeNewswire) +7.84%
May-29-24 09:35AM	Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround (Zacks) +8.70%
08:00AM	AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan (GlobeNewswire)
May-14-24 04:05PM	AEON Biopharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 09:35AM	AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.21%
08:00AM	AEON Biopharma Provides Update on Development Pipeline (GlobeNewswire)
May-03-24 04:08PM	US Equity Markets Close Higher Friday Following Weak Jobs Report (MT Newswires) -49.40%
03:55PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires)
02:37PM	Top Midday Decliners (MT Newswires)
09:05AM	Sector Update: Health Care Stocks Mixed Pre-Bell Friday (MT Newswires)
08:31AM	AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial (MT Newswires)
07:00AM	AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine (GlobeNewswire)
Mar-30-24 10:53PM	CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
Mar-29-24 04:15PM	AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
03:45PM	AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 04:30PM	AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine (GlobeNewswire) -11.60% -12.57%
04:29PM	AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements (GlobeNewswire)
Jan-18-24 04:05PM	AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference (GlobeNewswire) +10.35%
Dec-12-23 08:00AM	AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine (GlobeNewswire)
Nov-15-23 04:49AM	AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements (GuruFocus.com) +7.61%
Nov-13-23 08:15AM	AEON Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 04:05PM	AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine (GlobeNewswire)
Aug-29-23 08:00AM	AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress® (GlobeNewswire)
Aug-24-23 08:00AM	AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache (GlobeNewswire) +14.91%
Aug-16-23 07:00AM	Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma (GlobeNewswire) +7.06%
Jul-24-23 07:00AM	AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update (GlobeNewswire) -15.13%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LYNCH TIMOTHY P	10% Owner	Aug 19 '26	Buy	0.21	1,150,000	243,455	6,500,000	Aug 21 07:41 PM

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

PresidentMr. Robert Bancroft

Chief Legal & Strategy Officer and Corporate SecretaryMr. Alex Wilson

Chief Medical OfficerDr. Chad K. Oh M.D.

Chief Financial OfficerMr. John A. Bencich M.B.A.

Chief Accounting OfficerMs. Jennifer Sy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AEON

AEON Biopharma Inc

Upgrade your Finviz experience